Validation across three independent BLCA cohorts consistently reproduced these findings, collectively suggesting FAM174B overexpression may characterize immunologically quiescent bladder tumors with limited immune cell engagement. This evidence concerns the gene FAM174B and bladder transitional cell carcinoma.